Opens in a new tab or window The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the bispecific T-cell engager blinatumomab ...

A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) ...

Next, he turns to a study of blinatumomab (BLIN) in pediatric ALL, which was presented during the ASH plenary session. BLIN improved outcomes for children with standard-risk B-cell ALL (B-ALL ...

Molecular Partners' DARPin platform shows promise, but future funding is uncertain. Learn why MOLN stock could be a risky, ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

The association has set a fundraising target of RM1.8 million, aimed at providing vital treatments, including the possibility ...

Research has shown that we need to give different treatment to babies that are under 1 year old when they are diagnosed. This information is for children over 1. Your hospital consultant can give you ...

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...

Chemotherapy is a treatment used to kill cancer cells. It involves taking one or more of a type of drug that interferes with the DNA of fast-growing cells. These drugs are subdivided into specific ...